MARIELA BLUM MURPHY

TitleAssistant Professor
InstitutionMD Anderson
DepartmentGI Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg. 2020 08; 272(2):311-318. PMID: 32675544.
      Citations: 1     Fields:    Translation:HumansCells
    2. Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Mansfield P, Ajani JA, Badgwell BD. Tumor Regression Grade in Gastric Cancer After Preoperative Therapy. J Gastrointest Surg. 2020 Jun 15. PMID: 32542556.
      Citations:    Fields:    
    3. Stark AP, Estrella JS, Chiang YJ, Das P, Minsky BD, Blum Murphy MA, Ajani JA, Mansfield P, Badgwell BD, Ikoma N. Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. J Surg Oncol. 2020 Sep; 122(3):422-432. PMID: 32462681.
      Citations:    Fields:    Translation:Humans
    4. Mizrak Kaya D, Nogueras González GM, Harada K, Blum Murphy MA, Lee JH, Bhutani MS, Weston B, Thomas I, Rogers JE, Das P, Badgwell BD, Ajani JA. Efficacy of Three-Drug Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma. Oncology. 2020; 98(8):542-548. PMID: 32434189.
      Citations:    Fields:    Translation:Humans
    5. Rogers JE, Xiao L, Trail A, Blum Murphy M, Palmer M, Ajani JA. Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. Oncology. 2020; 98(5):289-294. PMID: 32097933.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    6. Blum Murphy M, Ikoma N, Wang X, Estrella J, Roy-Chowdhuri S, Das P, Minsky BD, Song S, Mansfield P, Ajani J, Badgwell B. Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology. Ann Surg Oncol. 2020 Aug; 27(8):2806-2811. PMID: 31974712.
      Citations:    Fields:    
    7. Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Zhao M, Bhutani MS, Nguyen QN, Swisher SG, Ikoma N, Badgwell BD, Hofstetter WL, Ajani JA. Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg. 2019 Jun 07. PMID: 31188215.
      Citations:    Fields:    
    8. Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, Wang Y, Scott A, Ma L, Huo L, Vicente D, Blum Murphy M, Shanbhag N, Tatlonghari G, Thomas I, Rogers J, Kobayashi M, Vykoukal J, Estrella JS, Roy-Chowdhuri S, Han G, Zhang S, Mao X, Song X, Zhang J, Gu J, Johnson RL, Calin GA, Peng G, Lee JS, Hanash SM, Futreal A, Wang Z, Wang L, Ajani JA. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020 01; 69(1):18-31. PMID: 31171626.
      Citations: 3     Fields:    Translation:Humans
    9. Rogers JE, Xiao L, Amlashi FG, Elimova E, Blum Murphy MA, Sanders E, Shanbhag N, Thomas I, Ajani JA. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. Oncology. 2019; 96(5):252-258. PMID: 30893708.
      Citations:    Fields:    Translation:Humans
    10. Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg. 2019 Jan 31. PMID: 30720506.
      Citations:    Fields:    
    11. Mizrak Kaya D, Nogueras-Gonzáles GM, Harada K, Amlashi FG, Thomas I, Rogers JE, Bhutani MS, Lee JH, Weston B, Minsky BD, Estrella JS, Blum Murphy MA, Matamoros A, Devine CE, Das P, Badgwell BD, Ajani JA. Potentially curable gastric adenocarcinoma treated without surgery. Eur J Cancer. 2018 07; 98:23-29. PMID: 29859338.
      Citations:    Fields:    Translation:Humans
    12. Amlashi FG, Wang X, Davila RE, Maru DM, Bhutani MS, Lee JH, Weston BR, Mizrak Kaya D, Vassilakopoulou M, Harada K, Blum Murphy MA, Rice DC, Hofstetter WL, Davila M, Nguyen QN, Ajani JA. Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology. 2018; 95(2):81-90. PMID: 29843157.
      Citations: 1     Fields:    Translation:Humans
    13. Blum Murphy MA, Qiao W, Mewada N, Wadhwa R, Elimova E, Takashi T, Ho L, Phan A, Baker J, Ajani J. A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. Am J Clin Oncol. 2018 04; 41(4):321-325. PMID: 26908161.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    14. Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. Target Oncol. 2018 02; 13(1):99-106. PMID: 29218623.
      Citations: 1     Fields:    Translation:Humans
    15. Blum Murphy M, Xiao L, Patel VR, Maru DM, Correa AM, G Amlashi F, Liao Z, Komaki R, Lin SH, Skinner HD, Vaporciyan A, Walsh GL, Swisher SG, Sepesi B, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Ajani JA. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113. PMID: 28885712.
      Citations: 7     Fields:    Translation:Humans
    16. Mizrak Kaya D, Wang X, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella JS, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Matamoros A, Sagebiel T, Wu CC, Rogers JE, Thomas I, Maru DM, Skinner HD, Badgwell BD, Hofstetter WL, Ajani JA. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. Oncology. 2017; 93(4):243-248. PMID: 28683449.
      Citations: 3     Fields:    Translation:Humans
    17. Xi M, Xu C, Liao Z, Hofstetter WL, Blum Murphy M, Maru DM, Bhutani MS, Lee JH, Weston B, Komaki R, Lin SH. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017 08; 124(2):318-324. PMID: 28687396.
      Citations: 8     Fields:    Translation:Humans
    18. Bozkurt M, Amlashi FG, Blum Murphy M. The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction. Minerva Chir. 2017 Aug; 72(4):317-333. PMID: 28415835.
      Citations: 1     Fields:    Translation:Humans
    19. Blum Murphy MA, Elimova E, Ajani JA. Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Rev Gastroenterol Hepatol. 2016; 10(3):383-92. PMID: 26560689.
      Citations: 3     Fields:    Translation:Humans
    20. Pujara D, Mansfield P, Ajani J, Blum M, Elimova E, Chiang YJ, Das P, Badgwell B. Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. J Surg Oncol. 2015 Dec; 112(8):883-7. PMID: 26482869.
      Citations: 6     Fields:    Translation:Humans
    21. Elimova E, Shiozaki H, Slack RS, Chen HC, Wadhwa R, Sudo K, Charalampakis N, Hiremath A, Estrella JS, Matamoros A, Sagebiel T, Das P, Rogers JE, Garris JL, Blum MA, Badgwell B, Ajani JA. Early versus Delayed Therapy of Advanced Gastric Cancer Patients--Does It Make a Difference? Oncology. 2015; 89(4):215-20. PMID: 26159599.
      Citations: 1     Fields:    Translation:Humans
    22. Badgwell B, Blum M, Estrella J, Chiang YJ, Das P, Matamoros A, Fournier K, Mansfield P, Ajani J. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg. 2015 Jul; 221(1):83-90. PMID: 26002780.
      Citations: 8     Fields:    Translation:Humans
    23. Badgwell B, Roy-Chowdhuri S, Chiang YJ, Matamoros A, Blum M, Fournier K, Mansfield P, Ajani J. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol. 2015 Jun; 111(7):875-81. PMID: 25872485.
      Citations: 7     Fields:    Translation:Humans
    24. Shiozaki H, Slack R, Sudo K, Elimova E, Wadhwa R, Chen HC, Skinner HD, Komaki R, Lee JH, Weston B, Bhutani MS, Blum MA, Rogers JE, Maru DM, Hofstetter WL, Ajani JA. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology. 2015; 88(6):332-6. PMID: 25765098.
      Citations:    Fields:    Translation:Humans
    25. Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: a 2014 update. World J Gastroenterol. 2014 Oct 14; 20(38):13637-47. PMID: 25320502.
      Citations: 13     Fields:    Translation:Humans
    26. Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, Blum MA, Lee JH, Bhutani MS, Weston B, Ross WA, Komaki R, Rice DC, Swisher SG, Hofstetter WL, Maru DM, Skinner HD, Ajani JA. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol. 2014 Oct 20; 32(30):3400-5. PMID: 25225435.
      Citations: 17     Fields:    Translation:Humans
    27. Taketa T, Sudo K, Correa AM, Wadhwa R, Shiozaki H, Elimova E, Campagna MC, Blum MA, Skinner HD, Komaki RU, Lee JH, Bhutani MS, Weston BR, Rice DC, Swisher SG, Maru DM, Hofstetter WL, Ajani JA. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014 Aug; 12(8):1139-44. PMID: 25099446.
      Citations: 4     Fields:    Translation:Humans
    28. Shiozaki H, Sudo K, Xiao L, Wadhwa R, Elimova E, Hofstetter WL, Skinner HD, Lee JH, Weston B, Bhutani MS, Blum MA, Maru DM, Ajani JA. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology. 2014; 86(5-6):336-9. PMID: 24925190.
      Citations: 7     Fields:    Translation:Humans
    29. Wadhwa R, Elimova E, Shiozaki H, Sudo K, Blum MA, Estrella JS, Chen Q, Song S, Ajani JA. Anti-angiogenic agent ramucirumab: meaningful or marginal? Expert Rev Anticancer Ther. 2014 Apr; 14(4):367-79. PMID: 24605771.
      Citations: 3     Fields:    Translation:Humans
    30. Amini A, Ajani J, Komaki R, Allen PK, Minsky BD, Blum M, Xiao L, Suzuki A, Hofstetter W, Swisher S, Gomez D, Liao Z, Lee JH, Bhutani MS, Welsh JW. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14. PMID: 24197760.
      Citations: 14     Fields:    Translation:Humans
    31. Blum MA, Taketa T, Sudo K, Wadhwa R, Skinner HD, Ajani JA. Chemoradiation for esophageal cancer. Thorac Surg Clin. 2013 Nov; 23(4):551-8. PMID: 24199704.
      Citations: 4     Fields:    Translation:Humans
    32. Sudo K, Taketa T, Correa AM, Campagna MC, Wadhwa R, Blum MA, Komaki R, Lee JH, Bhutani MS, Weston B, Skinner HD, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol. 2013 Dec 01; 31(34):4306-10. PMID: 24145339.
      Citations: 15     Fields:    Translation:Humans
    33. Wadhwa R, Taketa T, Correa AM, Sudo K, Campagna MC, Blum MA, Komaki R, Skinner H, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher S, Hofstetter WL, Ajani JA. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology. 2013; 85(4):204-7. PMID: 24051869.
      Citations: 7     Fields:    Translation:Humans
    34. Francis AM, Sepesi B, Correa AM, Blum MA, Erasmus JJ, Lee JH, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Welsh JW, Swisher SG, Hofstetter WL. The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma. Ann Surg. 2013 Sep; 258(3):500-7. PMID: 24022442.
      Citations: 9     Fields:    Translation:Humans
    35. Suzuki A, Xiao L, Taketa T, Sudo K, Wadhwa R, Blum MA, Skinner H, Komaki R, Weston B, Lee JH, Bhutani MS, Rice DC, Maru DM, Erasmus J, Swisher SG, Hofstetter WL, Ajani JA. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol. 2013 Nov; 24(11):2854-9. PMID: 23994746.
      Citations: 5     Fields:    Translation:Humans
    36. Taketa T, Xiao L, Sudo K, Suzuki A, Wadhwa R, Blum MA, Lee JH, Weston B, Bhutani MS, Skinner H, Komaki R, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. Oncology. 2013; 85(2):95-9. PMID: 23860252.
      Citations: 5     Fields:    Translation:Humans
    37. Wadhwa R, Taketa T, Sudo K, Blum-Murphy M, Ajani JA. Ramucirumab: a novel antiangiogenic agent. Future Oncol. 2013 Jun; 9(6):789-95. PMID: 23718298.
      Citations: 12     Fields:    Translation:Humans
    38. Taketa T, Sudo K, Wadhawa R, Blum MM, Ajani JA. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013 Apr; 15(2):146-51. PMID: 23355076.
      Citations: 3     Fields:    Translation:Humans
    39. Wadhwa R, Taketa T, Sudo K, Blum MA, Ajani JA. Modern oncological approaches to gastric adenocarcinoma. Gastroenterol Clin North Am. 2013 Jun; 42(2):359-69. PMID: 23639645.
      Citations: 17     Fields:    Translation:HumansCells
    40. Blum MA, Takashi T, Suzuki A, Ajani JA. Management of localized gastric cancer. J Surg Oncol. 2013 Mar; 107(3):265-70. PMID: 23303654.
      Citations: 12     Fields:    Translation:Humans
    41. Cheedella NK, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welch J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. 2013 May; 24(5):1262-6. PMID: 23247658.
      Citations: 25     Fields:    Translation:Humans
    42. Murphy MA, Taketa T, Sudo K, Lee JH, Ajani JA. Surveillance for esophageal cancer: does it make sense? J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1590-2. PMID: 23221793.
      Citations:    Fields:    Translation:Humans
    43. Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012; 83(5):300-4. PMID: 22964903.
      Citations: 8     Fields:    Translation:Humans
    44. Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. 2012 Dec; 48(18):3396-404. PMID: 22853875.
      Citations: 6     Fields:    Translation:Humans
    45. Blum MA, Ajani JA. Chemoradiation: Gastro-oesophageal cancer--is CROSSing over so hard to do? Nat Rev Clin Oncol. 2012 Sep; 9(9):493-4. PMID: 22825372.
      Citations:    Fields:    Translation:Humans
    46. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012 Oct; 23(10):2638-2642. PMID: 22831985.
      Citations: 22     Fields:    Translation:Humans
    47. Suzuki A, Xiao L, Taketa T, Blum MA, Matamoros A, Chien PL, Mansfield PF, Fournier KF, Weston B, Lee JH, Bhutani MS, Estrella JS, Delclos ME, Krishnan S, Das P, Ajani JA. Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience. Oncology. 2012; 82(6):347-51. PMID: 22677933.
      Citations: 3     Fields:    Translation:Humans
    48. Hayashi Y, Blum MA, Ajani JA. Advanced gastroesophageal carcinoma: an update on the current therapeutic landscape. Onkologie. 2012; 35(4):204-9. PMID: 22488092.
      Citations: 2     Fields:    Translation:Humans
    49. Blum MA, Ajani JA. Therapy: localized gastric cancer--a CLASSIC shift in the paradigm? Nat Rev Gastroenterol Hepatol. 2012 Mar 06; 9(4):194-5. PMID: 22392288.
      Citations: 1     Fields:    Translation:Humans
    50. Ajani JA, Blum MA, Estrella JS, Das P, Fournier KF. Gastric cancer: apples will always be apples. J Clin Oncol. 2012 Mar 20; 30(9):1017-8; author reply 1019-20. PMID: 22331947.
      Citations: 3     Fields:    Translation:Humans
    51. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012; 82(2):108-13. PMID: 22328056.
      Citations: 12     Fields:    Translation:Humans
    52. Blum MA, Ajani JA. Many a mickle makes a muckle. Translating a gastric cancer phenotype into a bigger thing. Onkologie. 2011; 34(10):499-500. PMID: 21985847.
      Citations:    Fields:    Translation:Humans
    53. Blum M, Suzuki A, Ajani JA. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol. 2011 Jun; 7(6):715-26. PMID: 21675835.
      Citations: 9     Fields:    Translation:Humans
    54. Ajani JA, Blum MA, Welsh J, Hofstetter WL, Swisher SG. Celebrate or calibrate? We say calibrate. J Clin Oncol. 2011 Jul 01; 29(19):2732; author reply 2732-3. PMID: 21606421.
      Citations:    Fields:    Translation:Humans
    55. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Annals of Surgical Oncology.
    56. Current therapeutic approaches to localized carcinoma of the esophagus and gastroesophageal junction. Clinical Practice. 9:463-471.
    57. Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology (Switzerland).
    58. Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy. Oncology (Switzerland). 91:55-60.
    59. A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. American Journal of Clinical Oncology: Cancer Clinical Trials.
    60. Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. Annals of Surgical Oncology. 1-8.
    61. Adjunctive therapy of gastric cancer. ONCOLOGY (United States). 30.
    62. Targets by organ site.
    63. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy. Annals of Surgical Oncology. 23:626-632.
    64. Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. Annals of Surgical Oncology. 1-6.
    65. Ramucirumab for the treatment of gastroesophageal cancers. Expert Opinion on Orphan Drugs. 3:737-746.
    66. Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma. The Lancet Oncology. 17:1628-1629.
    67. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. European Journal of Cancer.
    68. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology (Switzerland).
    69. Survival rates in T1 and T2 gastric cancer. Journal of Surgical Oncology. 114:602-606.
    70. A nomogram to predict distant metastases after multimodality therapy for patients with localized esophageal cancer. JNCCN Journal of the National Comprehensive Cancer Network. 14:173-179.
    71. Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Annals of Surgical Oncology. 1-11.
    72. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer. Journal of Gastrointestinal Oncology. 7:499-505.
    73. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation. Oncology (Switzerland).
    74. Anal canal cancer. Expert Opinion on Orphan Drugs. 2:137-146.
    75. Targets by organ site.
    76. Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Review of Gastroenterology and Hepatology. 10:383-392.
    77. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Annals of Surgical Oncology. 1-6.
    78. Paraneoplastic neurological syndromes associated with gastric cancer. Clinical Journal of Gastroenterology. 5:355-360.
    BLUM MURPHY's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (149)
    Explore
    _
    Co-Authors (44)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _